within Pharmacolibrary.Drugs.ATC.P;

model P01AX05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600,            
    Vdp             = 0.01,
    k12             = 15,
    k21             = 15
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01AX05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mepacrine, also known as quinacrine, is an antimalarial drug historically used for the treatment and prophylaxis of malaria. It has also been used as an anthelmintic and in the treatment of giardiasis, lupus erythematosus, and rheumatoid arthritis. Mepacrine is largely obsolete today as an antimalarial due to development of newer agents and side effect profile, but is sometimes still used for non-malarial indications.</p><h4>Pharmacokinetics</h4><p>Estimation based on historical pharmacokinetic data and literature reviews for adults. No recent direct, peer-reviewed population PK studies with compartmental PK parameters in humans available.</p><h4>References</h4><ol><li><p>Brocks, DR, &amp; Mehvar, R (2003). Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. <i>Clinical pharmacokinetics</i> 42(15) 1359–1382. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342150-00004&quot;>10.2165/00003088-200342150-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14674788/&quot;>https://pubmed.ncbi.nlm.nih.gov/14674788</a></p></li><li><p>Lane, TR, et al., &amp; Ekins, S (2020). Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. <i>Antiviral research</i> 181 104863–None. DOI:<a href=&quot;https://doi.org/10.1016/j.antiviral.2020.104863&quot;>10.1016/j.antiviral.2020.104863</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32682926/&quot;>https://pubmed.ncbi.nlm.nih.gov/32682926</a></p></li><li><p>Ahn, M, et al., &amp; Prusiner, SB (2012). Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter. <i>PloS one</i> 7(7) e39112–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0039112&quot;>10.1371/journal.pone.0039112</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22768295/&quot;>https://pubmed.ncbi.nlm.nih.gov/22768295</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01AX05;
